Heart with atrial fibrillation pattern and NT-proBNP biomarker display

Decoding Heart Failure: How Atrial Fibrillation and NT-proBNP Levels Change the Diagnosis

Author's portrait.
Rhea Morgan in Health & Wellness July 2025 • 4 min read.

"Understand the connection between atrial fibrillation (AF) and NT-proBNP in diagnosing acute heart failure in dyspneic patients, and how it impacts diagnostic accuracy."


Heart failure is a complex condition, and diagnosing it accurately requires careful consideration of various factors. Among these, N-terminal pro-brain natriuretic peptide (NT-proBNP) has become a widely used biomarker for assessing heart failure. However, the presence of other conditions, such as atrial fibrillation (AF), can complicate the interpretation of NT-proBNP levels. Atrial fibrillation, a common heart rhythm disorder, often coexists with heart failure, making it crucial to understand how it influences NT-proBNP concentrations and, consequently, the accuracy of heart failure diagnoses.

Dyspnea, or shortness of breath, is a common symptom that prompts individuals to seek medical attention. In patients presenting with dyspnea, distinguishing between cardiac and non-cardiac causes is essential for appropriate management. NT-proBNP measurements can aid in this differentiation, but the influence of AF on NT-proBNP levels needs careful consideration. This is because AF can independently elevate NT-proBNP, potentially leading to overdiagnosis of heart failure in individuals whose dyspnea stems from other causes.

Recent research has delved into the intricate relationship between atrial fibrillation and NT-proBNP in the context of acute heart failure diagnosis. By examining a cohort of dyspneic patients, these studies have sought to clarify how AF affects NT-proBNP levels and whether it impacts the diagnostic performance of this biomarker. The findings from these investigations offer valuable insights for clinicians aiming to optimize their diagnostic strategies in patients with suspected heart failure and concurrent AF.

How Does Atrial Fibrillation Affect NT-proBNP Levels?

Heart with atrial fibrillation pattern and NT-proBNP biomarker display

Atrial fibrillation (AF) is known to increase NT-proBNP levels, regardless of whether heart failure is present. This increase can make it challenging to use NT-proBNP as a reliable diagnostic marker for heart failure in patients with AF. Studies have shown that the median NT-proBNP level is significantly higher in patients with AF compared to those without AF, even when both groups do not have heart failure.

The diagnostic accuracy of NT-proBNP for acute heart failure (AHF) is lower in patients with AF than in those without AF. This means that using a single NT-proBNP cutoff value can lead to misdiagnosis in AF patients. Researchers have explored different NT-proBNP cutoff points for diagnosing AHF in patients with and without AF to improve diagnostic accuracy.

  • Higher NT-proBNP Levels: AF is associated with elevated NT-proBNP, complicating heart failure diagnosis.
  • Reduced Diagnostic Accuracy: The presence of AF reduces the reliability of NT-proBNP in diagnosing heart failure.
  • Optimal Cutoff Points: Different NT-proBNP thresholds are needed for patients with and without AF.
Research indicates that different NT-proBNP cutoff points should be used for diagnosing AHF in patients with and without AF. For example, one study found that an optimal NT-proBNP cutoff of 3700 pg/mL in AF patients had a sensitivity of 74% and specificity of 65%, while a cutoff of 1900 pg/mL in non-AF patients had a sensitivity of 91% and specificity of 79%. This suggests that clinicians need to adjust their diagnostic criteria based on the presence of AF.

Making Informed Diagnostic Decisions

In conclusion, atrial fibrillation significantly influences NT-proBNP concentrations and the diagnostic accuracy of NT-proBNP in dyspneic patients. Clinicians should be aware of this interaction and use different NT-proBNP cutoff values for patients with and without AF. Further research is needed to refine these cutoff values and develop more accurate diagnostic strategies for heart failure in the presence of atrial fibrillation. By understanding these nuances, healthcare professionals can improve their diagnostic precision and provide better care for patients with suspected heart failure.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

Everything You Need To Know

1

What is the role of NT-proBNP in diagnosing heart failure?

NT-proBNP (N-terminal pro-brain natriuretic peptide) is a widely used biomarker for assessing heart failure. It helps distinguish between cardiac and non-cardiac causes of dyspnea (shortness of breath). Elevated levels of NT-proBNP often indicate the presence of heart failure. However, the accuracy of using NT-proBNP is influenced by other conditions, such as atrial fibrillation, which can independently elevate NT-proBNP levels.

2

How does atrial fibrillation affect NT-proBNP levels?

Atrial fibrillation (AF) is known to increase NT-proBNP levels, regardless of whether heart failure is present. This elevation can complicate the use of NT-proBNP as a reliable diagnostic marker. Studies have shown that patients with AF have significantly higher median NT-proBNP levels compared to those without AF, even without heart failure. This means that the presence of AF can lead to a misdiagnosis of heart failure if not properly considered.

3

Why is it important to consider atrial fibrillation when using NT-proBNP for heart failure diagnosis?

It's crucial to consider atrial fibrillation (AF) because it significantly influences NT-proBNP concentrations. The presence of AF can lead to elevated NT-proBNP levels, even in the absence of heart failure. This can reduce the diagnostic accuracy of NT-proBNP, potentially resulting in overdiagnosis of heart failure in patients whose dyspnea arises from other causes. Clinicians must be aware of this interaction to avoid misinterpreting NT-proBNP results and ensure accurate diagnoses.

4

What are the implications of using different NT-proBNP cutoff points in diagnosing heart failure for patients with and without atrial fibrillation?

Using different NT-proBNP cutoff points for patients with and without atrial fibrillation (AF) is essential to improve diagnostic accuracy. Because AF independently elevates NT-proBNP, a single cutoff value can lead to misdiagnosis. For instance, research suggests that a higher NT-proBNP cutoff (e.g., 3700 pg/mL) might be optimal for diagnosing acute heart failure (AHF) in AF patients, while a lower cutoff (e.g., 1900 pg/mL) may be more appropriate for those without AF. This adjustment ensures that clinicians can more accurately identify AHF, accounting for the confounding effect of AF on NT-proBNP levels.

5

How can healthcare professionals improve the accuracy of heart failure diagnosis in patients with atrial fibrillation?

Healthcare professionals can improve the accuracy of heart failure diagnosis in patients with atrial fibrillation (AF) by recognizing the significant influence of AF on NT-proBNP concentrations and by using different NT-proBNP cutoff values. They should be aware that AF can independently elevate NT-proBNP, potentially leading to diagnostic errors. Further research is needed to refine these cutoff values and develop more accurate diagnostic strategies. This nuanced approach, incorporating the understanding of AF's impact, allows for more precise diagnoses and, consequently, better patient care in cases of suspected heart failure.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.